<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Kumar - Network-Based Drug Repurposing for Alzheimer's Disease</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Crimson+Pro:wght@400;600&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Crimson Pro', serif;
            line-height: 1.6;
            color: #2c3e50;
            background: #fff;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            padding: 60px 40px;
        }

        .back-link {
            font-family: 'JetBrains Mono', monospace;
            font-size: 0.85rem;
            color: #666;
            text-decoration: none;
            display: inline-block;
            margin-bottom: 40px;
        }

        .back-link:hover {
            color: #2c3e50;
        }

        header {
            margin-bottom: 60px;
            border-bottom: 1px solid #e0e0e0;
            padding-bottom: 30px;
        }

        h1 {
            font-size: 2.2rem;
            font-weight: 600;
            color: #1a1a1a;
            margin-bottom: 15px;
        }

        .subtitle {
            font-size: 1.1rem;
            color: #666;
            margin-bottom: 20px;
        }

        .tags {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            font-family: 'JetBrains Mono', monospace;
            font-size: 0.7rem;
            padding: 4px 10px;
            background: #f5f5f5;
            color: #555;
            border: 1px solid #ddd;
        }

        section {
            margin-bottom: 60px;
        }

        h2 {
            font-size: 1.6rem;
            margin-bottom: 20px;
            color: #1a1a1a;
        }

        h3 {
            font-size: 1.2rem;
            margin-bottom: 15px;
            margin-top: 30px;
            color: #1a1a1a;
        }

        h4 {
            font-size: 1rem;
            margin-bottom: 10px;
            margin-top: 20px;
            color: #1a1a1a;
            font-weight: 600;
        }

        p {
            margin-bottom: 15px;
            color: #555;
            font-size: 1rem;
        }

        ul {
            margin-left: 20px;
            margin-bottom: 15px;
        }

        li {
            margin-bottom: 10px;
            color: #555;
        }

        .architecture-diagram {
            margin: 40px 0;
            padding: 30px;
            background: #fafafa;
            border: 1px solid #e0e0e0;
        }

        .metrics {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }

        .metric-card {
            padding: 20px;
            border: 1px solid #e0e0e0;
        }

        .metric-value {
            font-size: 2rem;
            font-weight: 600;
            color: #1a1a1a;
            margin-bottom: 5px;
        }

        .metric-label {
            font-size: 0.9rem;
            color: #666;
        }

        .approach-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }

        .approach-box {
            padding: 25px;
            background: #fafafa;
            border: 1px solid #e0e0e0;
        }

        .approach-box h4 {
            margin-top: 0;
        }

        .enrichment-table {
            margin: 30px 0;
            padding: 25px;
            background: #fafafa;
            border: 1px solid #e0e0e0;
        }

        .enrichment-table h4 {
            margin-top: 0;
            margin-bottom: 15px;
        }

        .drug-box {
            margin: 20px 0;
            padding: 20px;
            background: #fff;
            border: 1px solid #ddd;
        }

        .drug-box h4 {
            margin-top: 0;
        }

        code {
            font-family: 'JetBrains Mono', monospace;
            font-size: 0.85rem;
            background: #f5f5f5;
            padding: 2px 6px;
            color: #333;
        }

        @media (max-width: 768px) {
            .container {
                padding: 40px 20px;
            }

            h1 {
                font-size: 1.8rem;
            }

            .metrics,
            .approach-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Portfolio</a>

        <header>
            <h1>Network-Based Drug Repurposing for Alzheimer's Disease</h1>
            <p class="subtitle">End-to-End Pipeline Integrating Network Diffusion, Mendelian Randomization, and Graph Topology</p>
            <div class="tags">
                <span class="tag">Network Medicine</span>
                <span class="tag">Drug Repurposing</span>
                <span class="tag">Random Walk with Restart</span>
                <span class="tag">Mendelian Randomization</span>
                <span class="tag">Louvain Communities</span>
                <span class="tag">Betweenness Centrality</span>
                <span class="tag">Label Propagation</span>
                <span class="tag">Network Diffusion</span>
                <span class="tag">PPI Networks</span>
                <span class="tag">STRING Database</span>
                <span class="tag">Graph Theory</span>
                <span class="tag">Network Topology</span>
                <span class="tag">Causal Inference</span>
                <span class="tag">eQTL</span>
                <span class="tag">GWAS</span>
                <span class="tag">Disease Module Discovery</span>
                <span class="tag">Alzheimer's Disease</span>
                <span class="tag">Tyrosine Kinase Inhibitors</span>
                <span class="tag">GO Enrichment</span>
                <span class="tag">Statistical Validation</span>
                <span class="tag">DrugBank</span>
                <span class="tag">Null Model Testing</span>
                <span class="tag">Python</span>
                <span class="tag">NetworkX</span>
            </div>
        </header>

        <section id="overview">
            <h2>Overview</h2>
            <p>Alzheimer's disease drug development faces a critical failure rate—over 99% of clinical trials fail, with traditional target-based approaches unable to capture the complex, network-level pathophysiology underlying neurodegeneration. Most pharmaceutical R&D focuses on single molecular targets despite growing evidence that AD involves dysregulation across interconnected biological pathways including synaptic dysfunction, immune activation, lipid metabolism, and amyloid processing.</p>

            <p>Built an end-to-end computational drug repurposing pipeline that integrates three complementary network-based strategies: proximity-based targeting using network diffusion from AD genetic risk genes, causality-based filtering via Mendelian randomization to prioritize genetically validated targets, and topology-based selection emphasizing bottleneck proteins that bridge functional communities. By systematically comparing drug prioritization across these mechanistically distinct hypotheses, the pipeline identifies FDA-approved compounds whose targets converge on statistically validated, biologically coherent disease modules rather than relying on single-gene associations.</p>

            <div class="metrics">
                <div class="metric-card">
                    <div class="metric-value">16,201</div>
                    <div class="metric-label">Proteins in Network</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">500</div>
                    <div class="metric-label">Disease Module Proteins</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">p=0.001</div>
                    <div class="metric-label">Statistical Validation</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">3</div>
                    <div class="metric-label">Consensus Drugs</div>
                </div>
            </div>
        </section>

        <section id="approach">
            <h2>Three Complementary Hypotheses</h2>
            <p>Rather than committing to a single targeting strategy, the pipeline systematically evaluates three mechanistically distinct network-based hypotheses for AD drug repurposing, each capturing different aspects of disease biology:</p>

            <div class="approach-grid">
                <div class="approach-box">
                    <h4>Hypothesis 1: Proximity-Based Targeting</h4>
                    <p>Drugs targeting proteins proximal to AD genetic risk genes in the protein-protein interaction network engage disease-relevant pathways. Used Random Walk with Restart (RWR) diffusion from 75 AD seed genes to identify a 500-protein disease module, then ranked drugs by number of module targets.</p>
                </div>

                <div class="approach-box">
                    <h4>Hypothesis 2: Causality-Based Targeting</h4>
                    <p>Drugs targeting proteins with causal genetic evidence for AD risk offer higher probability of clinical efficacy. Applied Mendelian Randomization using GTEx eQTL data and AD GWAS to identify 43 proteins with statistically significant causal relationships, prioritizing drugs targeting this filtered set.</p>
                </div>

                <div class="approach-box">
                    <h4>Hypothesis 3: Topology-Based Targeting</h4>
                    <p>Drugs targeting bottleneck proteins bridging functional communities disrupt disease propagation more effectively than peripheral targets. Used Louvain community detection to partition the disease module into 20 functional clusters, then identified 50 high-betweenness bottleneck proteins as strategic targets.</p>
                </div>
            </div>
        </section>

        <section id="architecture">
            <h2>Technical Architecture</h2>

            <div class="architecture-diagram">
                <div style="font-family: 'JetBrains Mono', monospace; font-size: 0.85rem; line-height: 1.8;">
                    <div style="margin-bottom: 20px;">
                        <strong>Data Sources</strong><br>
                        STRING v12 PPI Network (16,201 proteins)<br>
                        75 AD Seed Genes (ADSP)<br>
                        AD GWAS (Kunkle et al. 2019)<br>
                        GTEx eQTL (Brain Cortex)<br>
                        DrugBank Drug-Target Data
                    </div>
                    
                    <div style="text-align: center; color: #999; margin: 10px 0;">↓</div>
                    
                    <div style="margin-bottom: 20px;">
                        <strong>Network Preprocessing</strong><br>
                        High-confidence interactions (score > 900)<br>
                        Filtered network: ~12,000 proteins
                    </div>
                    
                    <div style="text-align: center; color: #999; margin: 10px 0;">↓</div>
                    
                    <div style="margin-bottom: 20px;">
                        <strong>Three Parallel Approaches</strong>
                    </div>
                    
                    <div style="padding-left: 20px; margin-bottom: 20px;">
                        <strong>Approach 1: Proximity-Based</strong><br>
                        Random Walk with Restart (70% walk, 30% restart)<br>
                        → 500-protein disease module<br>
                        → Drug ranking by module target count
                    </div>
                    
                    <div style="padding-left: 20px; margin-bottom: 20px;">
                        <strong>Approach 2: Causality-Based</strong><br>
                        Mendelian Randomization (Wald Ratio)<br>
                        → 43 causal proteins (p < 0.05)<br>
                        → Drug ranking by causal target count
                    </div>
                    
                    <div style="padding-left: 20px; margin-bottom: 20px;">
                        <strong>Approach 3: Topology-Based</strong><br>
                        Louvain community detection (20 communities)<br>
                        Betweenness centrality<br>
                        → 50 bottleneck proteins<br>
                        → Drug ranking by bottleneck target count
                    </div>
                    
                    <div style="text-align: center; color: #999; margin: 10px 0;">↓</div>
                    
                    <div style="margin-bottom: 20px;">
                        <strong>Statistical Validation</strong><br>
                        Label propagation convergence analysis<br>
                        Random seed null model (1,000 permutations)<br>
                        GO enrichment (DAVID)<br>
                        KEGG pathway overlap
                    </div>
                    
                    <div style="text-align: center; color: #999; margin: 10px 0;">↓</div>
                    
                    <div>
                        <strong>Consensus Drug Candidates</strong><br>
                        Cross-method validation<br>
                        Top 100 drugs per approach<br>
                        3 drugs in all three rankings
                    </div>
                </div>
            </div>
        </section>

        <section id="implementation">
            <h2>Implementation & Validation</h2>

            <h3>Disease Module Construction</h3>
            <p>Applied label propagation via Random Walk with Restart on the STRING v12 protein-protein interaction network, starting from 75 AD genetic risk genes (ADSP). The diffusion algorithm iteratively propagated disease signal across network edges with 70% probability of following connections and 30% probability of restarting at seed genes, converging to stable propagation scores for all 16,201 proteins. Ranking proteins by propagated score revealed a right-skewed distribution with concentrated signal around a small subset of high-scoring proteins, indicating localized disease module formation rather than diffuse network spread.</p>

            <h3>Statistical Validation via Null Model</h3>
            <p>To rigorously test whether the identified disease module represents genuine genetic signal versus generic network connectivity, implemented a random seed null model. Generated 1,000 random seed sets of equal size (n=17) and computed mean rank for each random trial. The observed mean rank of true AD GWAS seeds was 9—placing them among the top-ranked proteins—while the null distribution centered around rank 8,150 (random expectation). None of the 1,000 random trials achieved a mean rank as low as the true seeds, yielding empirical p=0.001 and confirming non-random concentration of diffusion signal around AD genetic risk loci.</p>

            <h3>Biological Coherence Assessment</h3>
            <p>To evaluate whether the statistically validated disease module captures AD-relevant biology, performed Gene Ontology enrichment analysis on the top 500 label propagation-ranked proteins using DAVID Functional Annotation Tool. Significant enrichment emerged for biological processes directly implicated in AD pathophysiology: endocytosis (fold enrichment 9.13, FDR < 1e-26), receptor-mediated endocytosis (14.84-fold, FDR < 1e-21), complement activation (24.67-fold, FDR < 1e-17), amyloid-beta clearance (32.74-fold, FDR ≈ 0), and lipid transport pathways including reverse cholesterol transport and HDL remodeling (28-33-fold enrichment, FDR ≈ 0). This functional coherence validates that network proximity reflects disease biology rather than generic connectivity artifacts.</p>

            <h3>Mendelian Randomization for Causal Filtering</h3>
            <p>Integrated genetic causal inference to prioritize disease module proteins with evidence linking their expression levels to AD risk. Extracted eQTL data from GTEx (brain cortex tissue) for proteins in the RWR-defined disease module and performed two-sample Mendelian Randomization using Wald Ratio tests with AD GWAS summary statistics (Kunkle et al. 2019). Of 388 testable proteins with valid genetic instruments (78% of module), 43 proteins exhibited statistically significant causal relationships (p < 0.05), representing an 11% retention rate after causal filtering. These proteins formed a causally implicated subnetwork enriched for immune, endocytosis, metabolism, and signal transduction pathways.</p>

            <h3>Topology-Based Bottleneck Identification</h3>
            <p>To identify strategic intervention points within the disease module, applied Louvain community detection to partition the 500-protein network into 20 functional communities representing distinct biological processes. Computed betweenness centrality—quantifying how frequently each protein appears on shortest paths between other proteins—to identify bottleneck nodes bridging these communities. Selected the top 50 proteins by betweenness as topology-based targets, hypothesizing that disrupting these inter-community bridges would more effectively impair disease propagation than targeting within-community proteins.</p>

            <h3>Drug-Target Integration and Prioritization</h3>
            <p>Queried DrugBank to identify FDA-approved and investigational drugs with known protein targets, then ranked drugs independently according to each hypothesis: (1) proximity-based ranking by number of targets in the 500-protein RWR module, (2) causality-based ranking by number of targets among the 43 Mendelian Randomization-validated proteins, and (3) topology-based ranking by number of targets among the 50 bottleneck proteins. Generated top 100 drug lists for each approach and computed pairwise overlap to assess agreement across methods.</p>
        </section>

        <section id="results">
            <h2>Results & Consensus Candidates</h2>

            <div class="metrics">
                <div class="metric-card">
                    <div class="metric-value">500</div>
                    <div class="metric-label">Proximity Module Proteins</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">43</div>
                    <div class="metric-label">Causal Proteins (MR)</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">50</div>
                    <div class="metric-label">Bottleneck Proteins</div>
                </div>
                <div class="metric-card">
                    <div class="metric-value">60%</div>
                    <div class="metric-label">Baseline-Causal Overlap</div>
                </div>
            </div>

            <p>Comparison of top 100 drugs across the three prioritization strategies revealed partial but structured overlap. The strongest agreement was between proximity-based and causality-based rankings (60% overlap in top 50, Jaccard index 0.60), indicating that proteins proximal to AD risk genes are enriched for genetic causal evidence. Topology-based rankings showed moderate overlap with both methods (39% with proximity, 48% with causality), suggesting that bottleneck proteins capture complementary network information beyond local proximity or genetic causality alone.</p>

            <p>Three drugs appeared in all three top-100 rankings, representing consensus candidates supported by proximity, causality, and topology simultaneously:</p>

            <div class="drug-box">
                <h4>Bosutinib (DB06616)</h4>
                <p><strong>Status:</strong> FDA-approved for chronic myelogenous leukemia (CML)<br>
                <strong>Mechanism:</strong> Tyrosine kinase inhibitor targeting Src-family kinases (Src, Lyn, Hck) and Bcr-Abl<br>
                <strong>Module Targets:</strong> EGFR, FYN, SRC, SYK<br>
                <strong>Ranking:</strong> #1 proximity, #3 causal, #2 topology</p>
            </div>

            <div class="drug-box">
                <h4>Erlotinib (DB00530)</h4>
                <p><strong>Status:</strong> FDA-approved for non-small cell lung cancer (NSCLC)<br>
                <strong>Mechanism:</strong> EGFR tyrosine kinase inhibitor<br>
                <strong>Module Targets:</strong> EGFR, nuclear receptor pathways<br>
                <strong>Ranking:</strong> #7 proximity, #12.5 causal, #8.5 topology</p>
            </div>

            <div class="drug-box">
                <h4>Additional Consensus: Dasatinib, Imatinib</h4>
                <p>Multiple tyrosine kinase inhibitors appeared in top rankings across at least two methods, including Dasatinib (approved for leukemia, targeting Src/Bcr-Abl) and Imatinib (approved for leukemia, targeting Bcr-Abl/c-Kit). The recurrent emergence of kinase inhibitors across mechanistically distinct prioritization strategies suggests dysregulated kinase signaling represents a convergent and potentially actionable component of AD network pathophysiology.</p>
            </div>

            <div class="enrichment-table">
                <h4>Top GO Biological Process Enrichment (500-Protein Module)</h4>
                <ul style="margin-bottom: 0;">
                    <li><strong>Endocytosis:</strong> 45 proteins, 9.13-fold enrichment, FDR 8.43×10⁻²⁶</li>
                    <li><strong>Receptor-mediated endocytosis:</strong> 28 proteins, 14.84-fold, FDR 3.15×10⁻²¹</li>
                    <li><strong>Complement activation (classical pathway):</strong> 22 proteins, 18.61-fold, FDR 1.29×10⁻¹⁸</li>
                    <li><strong>Amyloid-beta clearance:</strong> 14 proteins, 32.74-fold, FDR ≈ 0</li>
                    <li><strong>Reverse cholesterol transport:</strong> 14 proteins, 32.74-fold, FDR ≈ 0</li>
                    <li><strong>Lipid transport:</strong> 26 proteins, 9.48-fold, FDR ≈ 0</li>
                </ul>
            </div>
        </section>

        <section id="technical-highlights">
            <h2>Key Technical Decisions</h2>

            <h3>Network Diffusion Over Direct Gene Lists</h3>
            <p>Rather than limiting analysis to known AD genes, implemented network diffusion to systematically expand from genetic seeds to their network neighborhoods. This approach captures proteins indirectly connected to AD risk loci that may represent druggable targets absent from direct genetic associations. The statistical validation via random seed null model ensures expanded targets maintain genuine disease signal rather than accumulating generic network hubs.</p>

            <h3>Complementary Hypothesis Testing</h3>
            <p>Designed the pipeline to systematically compare three mechanistically distinct targeting strategies rather than committing to a single approach. Proximity-based ranking emphasizes local network context, causality-based ranking prioritizes genetic validation, and topology-based ranking identifies bridging proteins with potential for systems-level disruption. The partial but non-random overlap across methods indicates each captures complementary biological information, with consensus candidates representing particularly robust repurposing opportunities.</p>

            <h3>Mendelian Randomization for Causal Filtering</h3>
            <p>Integrated Mendelian Randomization to leverage natural genetic variation as instrumental variables, establishing directional causal relationships between protein expression and AD risk. This approach addresses the limitation that network proximity alone cannot distinguish causally relevant proteins from correlative bystanders. The 43 causally validated proteins represent a genetically anchored subset with higher a priori probability of therapeutic efficacy, though the lenient p < 0.05 threshold (versus typical p < 0.01) reflects exploratory rather than definitive causal inference.</p>

            <h3>Topology as Complementary Signal</h3>
            <p>Incorporated graph-theoretic centrality measures to identify bottleneck proteins mediating information flow between functional communities. While proximity and causality emphasize "what" proteins to target, topology addresses "where" in the network to intervene for maximal disruption. The moderate but distinct overlap between topology-based and other rankings validates that network position provides orthogonal information to local proximity or genetic causality.</p>
        </section>

        <section id="learnings">
            <h2>Key Learnings</h2>

            <ul>
                <li><strong>Convergence on Kinase Signaling:</strong> Tyrosine kinase inhibitors (Bosutinib, Erlotinib, Dasatinib, Imatinib) emerged consistently across proximity, causality, and topology methods. This convergence suggests dysregulated Src-family kinase and EGFR signaling represents a robust network-level feature of AD pathophysiology, not an artifact of any single computational approach.</li>

                <li><strong>Genetic Anchoring Validates Module:</strong> The p=0.001 result from random seed null modeling demonstrates that network diffusion preserves genuine genetic signal rather than being dominated by generic connectivity. True AD GWAS seeds achieved mean rank 9 versus null expectation of 8,150, validating the localized concentration of disease signal around genetic risk loci.</li>

                <li><strong>Biological Coherence vs. Performance Metrics:</strong> Prioritized GO enrichment validation and pathway coherence over raw predictive performance, ensuring the disease module captures interpretable AD biology (endocytosis, complement, amyloid clearance, lipid transport) rather than optimizing for opaque model accuracy.</li>

                <li><strong>Partial Overlap Reflects Complementary Hypotheses:</strong> The incomplete but structured overlap across methods (60% baseline-causal, 39% baseline-topology) indicates each prioritization strategy captures different aspects of disease relevance. Consensus candidates appearing in multiple rankings represent targets robust to modeling assumptions.</li>

                <li><strong>Scalability Through Modular Design:</strong> Implemented independent modules for network diffusion, Mendelian Randomization, and topology analysis, enabling parallel exploration and facilitating adaptation to alternative PPI networks, disease contexts, or prioritization algorithms without pipeline redesign.</li>
            </ul>
        </section>

        <section id="future">
            <h2>Future Directions</h2>
            <ul>
                <li>Validate top candidates through retrospective analysis of insurance claims databases, comparing cognitive decline rates in cancer patients exposed to tyrosine kinase inhibitors versus matched controls</li>
                <li>Incorporate tissue-specific PPI networks and cell-type-resolved eQTL data to refine causal inference beyond bulk brain cortex expression</li>
                <li>Extend topology analysis beyond betweenness centrality to explore alternative centrality measures (eigenvector, PageRank, closeness) and assess robustness of bottleneck identification</li>
                <li>Integrate additional causal inference frameworks (mediation analysis, multivariable MR) to strengthen genetic evidence and address potential pleiotropy</li>
                <li>Scale to larger drug databases beyond DrugBank and incorporate clinical trial outcome data to assess real-world efficacy signals for prioritized candidates</li>
            </ul>
        </section>

        <a href="index.html" class="back-link">← Back to Portfolio</a>
    </div>
</body>
</html>
